161 related articles for article (PubMed ID: 37153687)
1. Antagonism between wild-type and mutant β-catenin controls hepatoblastoma differentiation via fascin-1.
Gest C; Sena S; Dif L; Neaud V; Loesch R; Dugot-Senant N; Paysan L; Piquet L; Robbe T; Allain N; Dembele D; Guettier C; Bioulac-Sage P; Rullier A; Le Bail B; Grosset CF; Saltel F; Lagrée V; Colnot S; Moreau V
JHEP Rep; 2023 May; 5(5):100691. PubMed ID: 37153687
[TBL] [Abstract][Full Text] [Related]
2. Deleting the β-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth.
Loesch R; Caruso S; Paradis V; Godard C; Gougelet A; Renault G; Picard S; Tanaka I; Renoux-Martin Y; Perret C; Taketo MM; Zucman-Rossi J; Colnot S
J Hepatol; 2022 Aug; 77(2):424-435. PubMed ID: 35257829
[TBL] [Abstract][Full Text] [Related]
3. Mutations and elevated transcriptional activity of conductin (AXIN2) in hepatoblastomas.
Koch A; Weber N; Waha A; Hartmann W; Denkhaus D; Behrens J; Birchmeier W; von Schweinitz D; Pietsch T
J Pathol; 2004 Dec; 204(5):546-54. PubMed ID: 15538750
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of glutamine synthetase and cytochrome P450 isoforms in human hepatoblastoma.
Schmidt A; Braeuning A; Ruck P; Seitz G; Armeanu-Ebinger S; Fuchs J; Warmann SW; Schwarz M
Toxicology; 2011 Mar; 281(1-3):7-14. PubMed ID: 21237236
[TBL] [Abstract][Full Text] [Related]
5. beta-Catenin associates with the actin-bundling protein fascin in a noncadherin complex.
Tao YS; Edwards RA; Tubb B; Wang S; Bryan J; McCrea PD
J Cell Biol; 1996 Sep; 134(5):1271-81. PubMed ID: 8794867
[TBL] [Abstract][Full Text] [Related]
6. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
[TBL] [Abstract][Full Text] [Related]
7. β-Catenin mutations as determinants of hepatoblastoma phenotypes in mice.
Zhang W; Meyfeldt J; Wang H; Kulkarni S; Lu J; Mandel JA; Marburger B; Liu Y; Gorka JE; Ranganathan S; Prochownik EV
J Biol Chem; 2019 Nov; 294(46):17524-17542. PubMed ID: 31597698
[TBL] [Abstract][Full Text] [Related]
8. Hepatocyte-Derived Lipocalin 2 Is a Potential Serum Biomarker Reflecting Tumor Burden in Hepatoblastoma.
Molina L; Bell D; Tao J; Preziosi M; Pradhan-Sundd T; Singh S; Poddar M; Luo J; Ranganathan S; Chikina M; Monga SP
Am J Pathol; 2018 Aug; 188(8):1895-1909. PubMed ID: 29920228
[TBL] [Abstract][Full Text] [Related]
9. Elevated expression of Wnt antagonists is a common event in hepatoblastomas.
Koch A; Waha A; Hartmann W; Hrychyk A; Schüller U; Waha A; Wharton KA; Fuchs SY; von Schweinitz D; Pietsch T
Clin Cancer Res; 2005 Jun; 11(12):4295-304. PubMed ID: 15958610
[TBL] [Abstract][Full Text] [Related]
10. Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas.
Wei Y; Fabre M; Branchereau S; Gauthier F; Perilongo G; Buendia MA
Oncogene; 2000 Jan; 19(4):498-504. PubMed ID: 10698519
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of SFRP1 is a protumorigenic event in hepatoblastoma and correlates with beta-catenin mutations.
Regel I; Eichenmüller M; Mahajan UM; Hagl B; Benitz S; Häberle B; Vokuhl C; von Schweinitz D; Kappler R
J Cancer Res Clin Oncol; 2020 May; 146(5):1153-1167. PubMed ID: 32189106
[TBL] [Abstract][Full Text] [Related]
12. YAP1 Withdrawal in Hepatoblastoma Drives Therapeutic Differentiation of Tumor Cells to Functional Hepatocyte-Like Cells.
Smith JL; Rodríguez TC; Mou H; Kwan SY; Pratt H; Zhang XO; Cao Y; Liang S; Ozata DM; Yu T; Yin Q; Hazeltine M; Weng Z; Sontheimer EJ; Xue W
Hepatology; 2021 Mar; 73(3):1011-1027. PubMed ID: 32452550
[TBL] [Abstract][Full Text] [Related]
13. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene.
Koch A; Denkhaus D; Albrecht S; Leuschner I; von Schweinitz D; Pietsch T
Cancer Res; 1999 Jan; 59(2):269-73. PubMed ID: 9927029
[TBL] [Abstract][Full Text] [Related]
14. Calpain induces N-terminal truncation of β-catenin in normal murine liver development: diagnostic implications in hepatoblastomas.
Lade A; Ranganathan S; Luo J; Monga SP
J Biol Chem; 2012 Jun; 287(27):22789-98. PubMed ID: 22613727
[TBL] [Abstract][Full Text] [Related]
15. The Hippo Effector Transcriptional Coactivator with PDZ-Binding Motif Cooperates with Oncogenic β-Catenin to Induce Hepatoblastoma Development in Mice and Humans.
Zhang S; Zhang J; Evert K; Li X; Liu P; Kiss A; Schaff Z; Ament C; Zhang Y; Serra M; Evert M; Chen N; Xu F; Chen X; Tao J; Calvisi DF; Cigliano A
Am J Pathol; 2020 Jul; 190(7):1397-1413. PubMed ID: 32283103
[TBL] [Abstract][Full Text] [Related]
16. Quantification of glypican 3, β-catenin and claudin-1 protein expression in hepatoblastoma and paediatric hepatocellular carcinoma by colour deconvolution.
Zhou S; Parham DM; Yung E; Pattengale P; Wang L
Histopathology; 2015 Dec; 67(6):905-13. PubMed ID: 25939253
[TBL] [Abstract][Full Text] [Related]
17. Dual β-Catenin and γ-Catenin Loss in Hepatocytes Impacts Their Polarity through Altered Transforming Growth Factor-β and Hepatocyte Nuclear Factor 4α Signaling.
Pradhan-Sundd T; Liu S; Singh S; Poddar M; Ko S; Bell A; Franks J; Huck I; Stolz D; Apte U; Ranganathan S; Nejak-Bowen K; Monga SP
Am J Pathol; 2021 May; 191(5):885-901. PubMed ID: 33662348
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of beta-catenin in hepatoblastoma and its clinical significance.
Archana B; D'Cruze L; Nazneen S; Thanka J; Scott JX
J Cancer Res Ther; 2022; 18(3):677-680. PubMed ID: 35900540
[TBL] [Abstract][Full Text] [Related]
19. HGF/c-Met related activation of β-catenin in hepatoblastoma.
Purcell R; Childs M; Maibach R; Miles C; Turner C; Zimmermann A; Sullivan M
J Exp Clin Cancer Res; 2011 Oct; 30(1):96. PubMed ID: 21992464
[TBL] [Abstract][Full Text] [Related]
20. Sporadic childhood hepatoblastomas show activation of beta-catenin, mismatch repair defects and p53 mutations.
Curia MC; Zuckermann M; De Lellis L; Catalano T; Lattanzio R; Aceto G; Veschi S; Cama A; Otte JB; Piantelli M; Mariani-Costantini R; Cetta F; Battista P
Mod Pathol; 2008 Jan; 21(1):7-14. PubMed ID: 17962810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
